Anjali Shukla

Anjali Shukla is a Supervisor in the Division of Product Quality Assessment XIV of the Office of Pharmaceutical Quality, CDER, FDA. She performs and supervises assessment of the chemistry, manufacturing and control programs of biotechnology products at all stages of drug development. She also performs FDA pre-license inspections of drug manufacturing facilities. Anjali serves as subject matter expert for insulin products, including biosimilars, and as the FDA liaison to the USP Insulin Expert Panel. Dr. Shukla is a member of the FDA Emerging Technology Team.